Pinned Tweet
“Why can’t I stop the fibrosis?”
“Why is this pill giving me diarrhoea?”
“Do these drugs *really* work?”
Patients with IPF or progressive ILD ask these 5 tough questions.
Let’s break them down — with honesty, evidence, and a dose of hope.🧵
#FIBRONEER #IPF #PulmonaryFibrosis #Nerandomilast #MedTwitter
1
4
323
Pradeep Rajagopalan retweeted
Experienced doctors do not always show their commitment through enthusiasm.
Sometimes scepticism reflects years of seeing what works, what fails, and what organisations are in danger of forgetting, writes @docib
bmj.com/content/395/bmj-2026…
Pradeep Rajagopalan retweeted
Listen: New journal club from Thorax on pleural disease.
thoraxbmj.podbean.com/e/pleu… #RespEd @ThoraxBMJ @PulmPEEPs /n
Pradeep Rajagopalan retweeted
Interested in the latest perspectives on lung cancer screening?
Register now for this upcoming webinar for a summary and discussion of the IARC Perspective on Lung Cancer Screening, published in the New England Journal of Medicine.
📅 Date: 23 November
Pradeep Rajagopalan retweeted
Great discussion by @DrHKantarjian and Ayalew Tefferi
on possible associations between #GLP1-1RA use and blood cancer incidence or progression, see @AjHematology @UTMDAnderson @MayoClinic
onlinelibrary.wiley.com/doi/…
Pradeep Rajagopalan retweeted
🟩RESPIROLOGY CASE REPORTS
The Blind Spot of GeneXpert MTB/RIF: Isoniazid-Resistant, Rifampicin-Susceptible Tuberculosis Detected on Phenotypic Drug Susceptibility Testing
onlinelibrary.wiley.com/doi/…
Pradeep Rajagopalan retweeted
A new single-cell atlas of non-small-cell #LungCancer found that standard staging alone can get a patient's risk wrong, in both directions.
A quarter of people staged as stage I were actually high risk. A small group of stage IV patients had survival as good as early stage disease.
This is exactly the point Lung Cancer Europe has long made through its Get Checked! campaign: a stage label is not the whole picture.
Full story: lungcancereurope.eu/news/why…
Pradeep Rajagopalan retweeted
【The Spectrum of Tuberculosis from Infection to Disease】
@HeartlandNTBC & @MayoClinicINFD
👉Really useful resource for all clinicians (PDF available online for FREE)!
👉heartlandntbc.org/wp-content…
#TBIntensive
#IDFellow #IDMedEd
Pradeep Rajagopalan retweeted
🟩RESPIROLOGY CASE REPORTS
Pulmonary Hamartoma Diagnosed by Transbronchial Mediastinal Cryobiopsy Additional to Needle Aspiration: A Case Report
onlinelibrary.wiley.com/doi/…
Pradeep Rajagopalan retweeted
What environmental and occupational exposures are risk factors for the development of interstitial lung disease (ILD) and should be included on ILD-specific exposure questionnaires?
Read the original research in #Journal_CHESTPulm: hubs.la/Q04yrPZN0
#MedEd #JournalCHEST #LungDisease #LungHealth
Pradeep Rajagopalan retweeted
Patients with lung cancers with cystic airspaces had 5-year cancer-specific survival comparable to noncystic non–small cell lung cancers, and retrospective simulations suggested that low-dose CT Lung-RADS 2022 recommendations enabled earlier diagnosis. bit.ly/4k8WpiR
Pradeep Rajagopalan retweeted
In this targeted editorial, Drs. Byrne and Hammer discuss lung cancer associated with cystic airspaces, including the application of Lung-RADS 2022. Read more here ➡️ bit.ly/4fhXHEP

ALT Here's a suitable alt text for the image: "Screenshot of a journal article titled 'Recognition of Lung Cancer Associated with Cystic Airspaces' by Suzanne C. Byrne and Mark M. Hammer, published in Radiology. It includes author photos, affiliations, and a link to another article by Mascalachi et al.
Pradeep Rajagopalan retweeted
The Pulmonary Embolism Reporting and Data System (PE-RADS) provides a standardized framework for reporting acute pulmonary embolism at CT scan and MR angiography to guide treatment considerations based on clot location and right heart imaging features.
Read the article in the November issue of the journal CHEST®: hubs.la/Q04CvMpr0
#MedEd #JournalCHEST
Pradeep Rajagopalan retweeted
NPJ Primary Care ✍️
The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care
#OpenAccess #Bronchiectasis #Nature
Read the article: doi.org/10.1038/s41533-026-0…
Pradeep Rajagopalan retweeted
The latest CHEST How I Do It discusses factors that can influence eosinophil counts and provides practical considerations for identifying underlying type 2 inflammation in patients with COPD in the clinic.
Read more: hubs.la/Q04Cvn7T0
#MedEd #JournalCHEST #COPD
Pradeep Rajagopalan retweeted
Different nailfold capillary changes in Rheumatic disease
#ACR26
Pradeep Rajagopalan retweeted
HOW TO READ A CT SCAN - simple approach 👇🏼
behindtheknife.org/watch/beh…
Pradeep Rajagopalan retweeted
IgG4 Guidelines👇
🔥Hot off the press for #ACR26 🔥
The @IgG4ward foundation guidelines on the treatment of IgG4-related disease
thelancet.com/journals/lanrh…
Free to read on lancet.com
Pradeep Rajagopalan retweeted
Thank you to Dr Ajay Wagh for an excellent presentation today on Advances in the Management of Recurrent Pleural Effusions!
🎥 Watch: drericlim.com/brompton-grand…
🎧 Listen: open.spotify.com/show/1mgh6u…
🔔 Subscribe: creators.spotify.com/pod/sho…
Pradeep Rajagopalan retweeted
Patients who used #depemokimab for uncontrolled #asthma experienced improved symptoms, activity, impact on daily life and well-being through 52 weeks, according to a poster presented at the #CHEST Annual Meeting. healio.com/news/allergy-asth…

ALT Patients who used #depemokimab for uncontrolled #asthma experienced improved symptoms, activity, impact on daily life and well-being through 52 weeks, according to a poster presented at the #CHEST Annual Meeting. https://www.healio.com/news/allergy-asthma/20261020/improvements-in-quality-of-life-in-asthma-emerge-earlypersist-with-depemokimab
Pradeep Rajagopalan retweeted
🗨️“Sputum color is a really cheap, easy, daily applicable biomarker that will tell you who is neutrophilic and who is not,” @ProfJDChalmers said at #CHEST2026. #bronchiectasis
vist.ly/5pjki

































